96 related articles for article (PubMed ID: 16637783)
1. New and emerging strategies for reducing cardiometabolic risk factors.
Rodgers PT; Fuke DC
Pharmacotherapy; 2006 May; 26(5 Pt 2):13S-31S; quiz 43S-45S. PubMed ID: 16637783
[TBL] [Abstract][Full Text] [Related]
2. Metabolic syndrome: treatment of hypertensive patients.
Israili ZH; Lyoussi B; Hernández-Hernández R; Velasco M
Am J Ther; 2007; 14(4):386-402. PubMed ID: 17667215
[TBL] [Abstract][Full Text] [Related]
3. Obesity and cardiometabolic syndrome in children.
Velasquez-Mieyer P; Neira CP; Nieto R; Cowan PA
Ther Adv Cardiovasc Dis; 2007 Oct; 1(1):61-81. PubMed ID: 19124396
[TBL] [Abstract][Full Text] [Related]
4. Evaluating and treating cardiometabolic risk factors: a case discussion.
Haines ST; Fuke DC; Lender D; Rodgers PT; Sysko SK
Pharmacotherapy; 2006 May; 26(5 Pt 2):32S-41S. PubMed ID: 16637784
[TBL] [Abstract][Full Text] [Related]
5. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
6. A novel peroxisome proliferator--activated receptor alpha/gamma dual agonist ameliorates dyslipidemia and insulin resistance in prediabetic rhesus monkeys.
Ding SY; Tigno XT; Braileanu GT; Ito K; Hansen BC
Metabolism; 2007 Oct; 56(10):1334-9. PubMed ID: 17884441
[TBL] [Abstract][Full Text] [Related]
7. Management issues in the metabolic syndrome.
Deedwania PC; Gupta R
J Assoc Physicians India; 2006 Oct; 54():797-810. PubMed ID: 17214277
[TBL] [Abstract][Full Text] [Related]
8. Dyslipidaemia in diabetic patients: time for a rethink.
Shepherd J
Diabetes Obes Metab; 2007 Sep; 9(5):609-16. PubMed ID: 17697054
[TBL] [Abstract][Full Text] [Related]
9. The treatment of dyslipidemia--what's left in the pipeline?
Rau O; Zettl H; Popescu L; Steinhilber D; Schubert-Zsilavecz M
ChemMedChem; 2008 Feb; 3(2):206-21. PubMed ID: 17963209
[TBL] [Abstract][Full Text] [Related]
10. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic management of isolated low high-density lipoprotein syndrome.
Bermúdez V; Cano R; Cano C; Bermúdez F; Arraiz N; Acosta L; Finol F; Pabón MR; Amell A; Reyna N; Hidalgo J; Kendall P; Manuel V; Hernández R
Am J Ther; 2008; 15(4):377-88. PubMed ID: 18645343
[TBL] [Abstract][Full Text] [Related]
12. Where are we with high-density lipoprotein raising and inhibition of cholesteryl ester transfer for heart disease risk reduction?
Schaefer EJ; Asztalos BF
Curr Opin Cardiol; 2007 Jul; 22(4):373-8. PubMed ID: 17556892
[TBL] [Abstract][Full Text] [Related]
13. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
[TBL] [Abstract][Full Text] [Related]
14. Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors.
Reasner CA
J Cardiovasc Pharmacol; 2008 Aug; 52(2):136-44. PubMed ID: 18670366
[TBL] [Abstract][Full Text] [Related]
15. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis.
Kontush A; Chapman MJ
Pharmacol Rev; 2006 Sep; 58(3):342-74. PubMed ID: 16968945
[TBL] [Abstract][Full Text] [Related]
16. Predictors of abdominal obesity and high susceptibility of cardiometabolic risk to its increments among Turkish women: a prospective population-based study.
Onat A; Sari I; Hergenç G; Yazici M; Uyarel H; Can G; Sansoy V
Metabolism; 2007 Mar; 56(3):348-56. PubMed ID: 17292723
[TBL] [Abstract][Full Text] [Related]
17. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
Sorensen SV; Frick KD; Wade A; Simko R; Burge R
Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic options for modifying cardiometabolic risk factors.
Aronne LJ
Am J Med; 2007 Mar; 120(3 Suppl 1):S26-34. PubMed ID: 17320519
[TBL] [Abstract][Full Text] [Related]
19. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors.
Rizzo M; Rizvi AA; Spinas GA; Rini GB; Berneis K
Expert Opin Investig Drugs; 2009 Oct; 18(10):1495-503. PubMed ID: 19758106
[TBL] [Abstract][Full Text] [Related]
20. New and emerging pharmacologic therapies for type 2 diabetes, dyslipidemia, and obesity.
Taylor JR; Dietrich E; Powell JG
Clin Ther; 2013 Jan; 35(1):A3-17. PubMed ID: 23328274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
